Table 4. Adjusted risk for glaucoma between statin groups in sensitivity analyses.

	Adjusted hazard ratio (95% confidence interval) and P-value for Outcomes
	Diagnosis of glaucoma	Use of anti-glaucoma drugs	Diagnosis of glaucoma or use of anti-glaucoma drugs
Without diabetes mellitusa
Low-potency statins (pravastatin, fluvastatin, pitavastatin, simvastatin)	1.0	1.0	1.0
High-potency statins (atorvastatin, rosuvastatin)	0.99 (0.83–1.17), P = 0.86	1.08 (0.82–1.42), P = 0.60	0.99 (0.85–1.16), P = 0.93
In users after switching to another statinb
Low-potency statins (pravastatin, fluvastatin, pitavastatin, simvastatin)	1.0	1.0	1.0
High-potency statins (atorvastatin, rosuvastatin)	1.07 (0.92–1.23), P = 0.77	1.07 (0.85–1.34), P = 0.58	1.06 (0.93–1.21), P = 0.40
40 years or olderb
Low-potency statins (pravastatin, fluvastatin, pitavastatin, simvastatin)	1.0	1.0	1.0
High-potency statins (atorvastatin, rosuvastatin)	1.10 (0.93–1.29), P = 0.26	1.08 (0.84–1.39), P = 0.53	1.08 (0.93–1.25), P = 0.34
Based on statin propertyb
Lipophilic statins (atorvastatin, fluvastatin, pitavastatin, simvastatin)	1.0	1.0	1.0
Hydrophilic statins (pravastatin, rosuvastatin)	0.95 (0.81–1.10), P = 0.48	1.10 (0.87–1.39), P = 0.45	0.97 (0.85–1.12), P = 0.72

^a Adjusted for age, sex, co-medications (antihypertensive drugs, antidepressants, benzodiazepines, anticoagulants, antiplatelet drugs, aspirin, anti-gout agents, and non-statins), comorbidities (hypertension, chronic heart failure, cerebrovascular disease, myocardial infarction, liver disease, renal disease, pulmonary disease, and cancer), and Charlson comorbidity score

^b Adjusted for age, sex, co-medications (antidiabetic drugs, antihypertensive drugs, antidepressants, benzodiazepines, anticoagulants, antiplatelet drugs, aspirin, anti-gout agents, and non-statins), comorbidities (diabetes mellitus, hypertension, chronic heart failure, cerebrovascular disease, myocardial infarction, liver disease, renal disease, pulmonary disease, and cancer), and Charlson comorbidity score